Endocrine-therapy

OTHER2 trials

Sponsors

Swiss Cancer Institute, Sonya Reid

Conditions

Breast CancerInvasive Mammary CarcinomaMetastatic Breast Cancer

Phase 2

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

RecruitingNCT05693766

Sonya ReidInvasive Mammary Carcinoma, Metastatic Breast Cancer

Start: 2023-09-28End: 2037-08-31Target: 64Updated: 2026-01-20

Phase 3

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

TerminatedNCT03905343

Swiss Cancer InstituteBreast Cancer

Start: 2019-06-25End: 2021-04-15Updated: 2021-06-16

Related Papers

Integrating gene signatures to guide HR+/HER2- MBC therapy in a diverse cohort (INSIGHT).

Journal of Clinical Oncology2025-05-28

Abstract OT-37-01: Ribociclib-endocrine therapy (ET) combination versus chemotherapy as 1st line treatment in patients (pts) with visceral metastatic breast cancer (BC). A multicenter, randomized phase III trial: SAKK 21/18

Cancer Research2021-02-15